

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
WO 2004/037371 A2

(51) International Patent Classification<sup>7</sup>: B01D  
(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.  
(21) International Application Number: PCT/US2003/033354  
(22) International Filing Date: 21 October 2003 (21.10.2003)  
(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data: 60/420,065 21 October 2002 (21.10.2002) US  
(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICAL N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).  
(72) Inventors; and  
(75) Inventors/Applicants (for US only): BARBIER, Ann, Johanna [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037 (US). WILSON, Sandy, J. [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). MAZUR, Curt [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).  
(74) Agents: ELDERKIN, Dianne et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE

### FAAH Assay



WO 2004/037371 A2

(57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.

## Assay for Determining the Activity of Fatty Acid Amide Hydrolase

### Field of the Invention

The present invention relates to methods for determining the activity of and identifying modulators of fatty acid amide hydrolases. More specifically, the invention relates to an assay, adaptable for high throughput screening, for compounds that alter fatty acid amide hydrolase activity.

### Background

10 The identification of anandamide (N-arachidonylethanolamine, AEA) as an endogenous ligand for the cannabinoid 1 receptor (Devane *et al.* (1992) *Science* 258:1946-1949) evoked much scientific interest in the function of bioactive lipids. Other examples of endogenous ligands are oleamide (*cis*-9,10-octadecenoamide), best known for its sleep-inducing properties (Cravatt *et al.* (1995) *Science* 268:1506-1509), and 2-arachidonoylglycerol, reported to be neuroprotective after brain injury (Panikashvili *et al.* (2001) *Nature* 413:527-531).

15 The main mechanism for the termination of the biological activity of anandamide is hydrolysis (Giuffrida *et al.* (2001) *J. Pharmacol. Expt. Ther.* 298:7-14); the existence of an anandamide transporter has also been proposed (Compton and Martin (1997) *J. Pharmacol. Expt. Ther.* 263:1138-1143).

20 The enzyme responsible for the hydrolysis of anandamide, oleamide and 2-arachidonoylglycerol was cloned in 1996 and named fatty acid amide hydrolase, or FAAH (Cravatt *et al.* (1996) *Nature* 384:87-87). FAAH (EC 3.5.1.4) is a membrane-bound enzyme with broad substrate specificity which is expressed in a wide variety of

human tissues and cell lines (for review see Ueda *et al.*, *Chem.Phys.Lipids.* 108: 107-121, (2000); Fowler *et al.*, *Biochem. Pharmacol.* 62: 517-526, (2001)).

Inhibitors of FAAH have been predicted to potentiate the effects of the endogenous cannabinoids and thereby promote sleep, muscle relaxation and analgesia (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). Efforts to identify useful inhibitors have been hampered by the lack of simple, reproducible assays suitable for high-throughput screening. Published methods include reversed phase HPLC (9) and thin-layer chromatography (Deutsch and Chin (1993) *Biochem. Pharmacol.* 46:791-796). A fluorescence displacement method has also been described (Thumser *et al.* (1997) *Biochem. Pharmacol.* 53:433-437). An additional assay relies on extraction of the hydrolysis product with a chloroform: methanol mixture (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86), followed by counting of radioactivity. However, the toxicity of the chloroform and the cumbersome physical manipulations of this method preclude the adaptation of this assay to a high-throughput format.

There is a need in the art, therefore, for improved FAAH assays, particularly those which can be adapted to high throughput screening, for determining the activity of FAAH and for identifying modulators of FAAH.

#### SUMMARY OF THE INVENTION

In one aspect, the instant invention provides methods for assaying the activity and amount of fatty acid amide hydrolase (FAAH) based on differences in the physicochemical and binding properties of a FAAH substrate, and the products of its hydrolysis. For example, anandamide is hydrolyzed by FAAH to arachidonic acid and ethanolamine (Fig. 1). In brief, a substrate, for example  $^3\text{H}$ -anandamide (ethanolamine 1- $^3\text{H}$ ), is incubated with a putative source of FAAH activity in a

reaction mixture. The FAAH activity, where present, catalyzes the hydrolysis of the substrate to form at least one radiolabeled hydrolysis product; the example substrate <sup>3</sup>H-anandamide is converted to labeled ethanolamine and unlabeled arachidonic acid. This labeled product and the labeled substrate are separated from each other and the 5 loss of labeled substrate, or preferably, the formation of labeled product, is measured. In certain preferred embodiments, the assays are performed in parallel or in sets wherein assays conducted in the presence of compounds to be tested for their ability to modulate the FAAH activity are compared with those conducted in the absence of the compounds to be tested. In other preferred embodiments samples from patients 10 can be assayed to determine if the FAAH activity is altered relative to a predetermined activity value.

In one aspect, the invention provides improved methods of measuring fatty acid amide hydrolase activity comprising combining a sample suspected of containing fatty acid amide hydrolase, with a labeled substrate of fatty acid amide hydrolase to 15 form a reaction mixture; incubating the reaction mixture under conditions which allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material wherein the selective binding material binds either the labeled substrate or the labeled product, but not both, thereby forming a 20 bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining the amount of labeled substrate hydrolyzed or the amount of labeled hydrolysis product formed; thereby indicating the fatty acid amide hydrolase activity of the sample.

In another aspect of the invention, methods are provided for identifying compounds which can modulate the activity of a FAAH enzyme. The methods comprise the steps of comparing the activity of a FAAH as assayed by the above method in the presence and in the absence of a test compound added to the reaction mixture; wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase. In various embodiments, the methods can be used to identify useful inhibitors or enhancers of FAAH activity.

The assay methods provided herein are adaptable for use in high throughput screening systems and are contemplated to be used in drug discovery efforts. High throughput screening using the assay methods of the present invention will allow libraries of test compounds (for example, libraries produced by techniques of combinatorial chemistry) to be used in rational screening programs to identify inhibitors and enhancers of FAAH activity which are useful as candidates for drugs

In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the

labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has

5 altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

These and other aspects of the present invention will be described in further detail in the Detailed Description set forth below.

## 10 BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Schematic diagram of a FAAH assay. The FAAH activity in T84 membranes converts anandamide [1-<sup>3</sup>H-ethanolamine] into radiolabeled ethanolamine and unlabeled arachidonic acid. The labeled anandamide and unlabeled arachidonic acid are selectively bound to charcoal in filterplates, whereas the

15 radiolabeled ethanolamine is collected in the flow-through and counted.

Figure 2 depicts an embodiment of a FAAH assay method. The reaction takes place in a reaction plate at room temperature. After 60 minutes, 60  $\mu$ l of the reaction mixture is transferred to a charcoal-filled filter plate. The filter plate is fitted on top of a Dynex plate; the assembly is then centrifuged for 5 minutes at 2000 rpm.

20 Figure 3: Arachidonic acid and anandamide, but not ethanolamine, bind to activated charcoal. Four different radiolabeled tracers were used: anandamide [1-<sup>3</sup>H-ethanolamine], anandamide [arachidonyl-5,6,8,9,11,12,14,15-<sup>3</sup>H], arachidonic acid [5,6,8,9,11,12,14,15-<sup>3</sup>H (N)] and ethanolamine ([2-<sup>14</sup>C] ethan-1-ol-2-amine hydrochloride). The tracers were incubated with membranes prepared from mouse

25 liver, T84 cells, HeLa cells or with vehicle, for 60 minutes at room temperature. The

percentage (calculated from the average of triplicate determinations  $\pm$  Standard Error of the mean (s.e.m.)) of total radioactivity recovered in the flow-through is shown.

**Figures 4A-4B:** Characterization of a preferred assay. A: Time-course of hydrolysis of  $^3$ H-anandamide by FAAH at room temperature and at 37<sup>0</sup> C. The 5 average of triplicate determinations  $\pm$  s.e.m. is shown. B: Determination of  $K_m$  for FAAH. T84 cell membranes (3.5  $\mu$ g protein per well) were incubated with a range of concentrations of  $^3$ H-anandamide. The reactions were carried out at room temperature in the presence or absence of inhibitors (either oleyl trimethylfluoro ketone (OTFMK) or methyl arachidonyl fluorophosphate (MAFP)). The experiment 10 where oleyl trimethylfluoro ketone was used to determine nonspecific binding is shown; the results with MAFP were comparable. Each point reflects the average of triplicate determinations  $\pm$  s.e.m.

#### **DETAILED DESCRIPTION OF THE INVENTION**

The reference works, patents, patent applications, and scientific literature, 15 including sequences denoted by their accession numbers (e.g. accession numbers to GenBank database sequences), that are referred to herein are hereby incorporated by reference in their entireties.

Various definitions are used throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words 20 specifically defined either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole, and as are typically understood by those skilled in the art. Where possible undefined words should be understood to have the usual meaning to the skilled artisan. Any conflict however between an art-understood definition of a word or phrase and a definition of the word

or phrase as specifically taught in this specification shall be resolved in favor of the latter.

Standard reference works setting forth the general principles of recombinant DNA technology known to those of skill in the art include Ausubel *et al.*, Current

5 Protocols in Molecular Biology, John Wiley & Sons, New York (2002); Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Plainview, New York (2001); Kaufman *et al.*, Eds., Handbook of Molecular and Cellular Methods in Biology and Medicine, CRC Press, Boca Raton (1995).

As used herein, a "label" is a composition detectable by spectroscopic, 10 photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes and fluorescent labels. Examples of radioisotopes that may be used in the method of the invention include  $^3\text{H}$  and  $^{14}\text{C}$ .

As used herein, "purified" refers to at least partial separation of a molecule from other molecules with which it is normally associated. For example, a purified 15 protein is a protein that is at least partially separated from other cellular material with which it is normally associated.

As used herein, the term "murine" means originating in a member of the family *Muridae*. A murine FAAH preferably originates in a mouse, or rat.

In a first aspect the invention provides methods of assaying a fatty acid amide 20 hydrolase (FAAH). In a presently preferred embodiment, the method of assay comprises the steps of combining a sample suspected of containing a FAAH with a labeled substrate of FAAH to form a reaction; incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, forming one or more labeled hydrolysis products; contacting the incubated 25 reaction mixture with a selective binding material; wherein the selective binding

material binds either the labeled substrate or a labeled hydrolysis product, but not both, to form a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining an amount of labeled substrate 5 hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.

The sample, in preferred embodiments, is a biological sample, or a sample comprising biological material, in particular biological membranes. In other preferred embodiments, the sample is from a purification step in the purification of FAAH from 10 a biological source. The sample comprises biological membranes or portions thereof, or comprises lipid bilayers, or artificial membrane systems, monolayers, vesicles or micelles. A sample in some embodiments comprises a purified or recombinant FAAH reconstituted into a phospholipid-containing reaction mixture.

The substrate may be any substrate, putative substrate, or substrate analog of 15 FAAH. The assay is also adapted for use to determine the utility of a compound as a substrate of FAAH. Substrates preferred for use in various embodiments of the present invention include, but are not limited to endocannabinoids or analogs thereof, fatty acid ethanolamides or analogs thereof, fatty acid primary amides or analogs thereof, and analogs of any of the foregoing labeled with a detectable label. Presently 20 preferred substrates of particular interest include, for example, anandamide, oleamide, and 2-arachidonoylglycerol.

The substrate may be radioisotopically labeled in any manner known in the art for labeling compounds for detection. Presently preferred isotopes, such as <sup>3</sup>H or <sup>14</sup>C, are readily detected via liquid scintillation counting and can facilitate adaptation of

the assays for high throughput drug screening. Synthetic substrates so labeled are readily available commercially or can be synthesized.

Other labels such as fluorescent labels capable of detection, for example fluorimetric detection, are also readily adapted to high throughput screening.

5 Preferred fluorescent labels are detectable in biological systems with both proteins and nucleic acids present, therefore preferred labels when assaying cruder cell lysates and homogenates possess both excitation and emission optima which are not masked by these other biological components. In one embodiment the unhydrolyzed labeled substrate has identical fluorescent properties with the hydrolysis product. It is also  
10 possible to design substrates wherein hydrolysis results in a change in fluorescence, for example, where a dye-dye interaction in the unhydrolyzed molecule is required to maintain a ground state. Such substrates are useful in conjunction with the present invention. Colorimetric labels are also contemplated for use herein. Generally, appropriate labels are those which do not alter the substrate's susceptibility to  
15 hydrolysis by the enzyme and for which detection systems have been developed.

Preferably the substrate is present at concentrations at vast excess relative to the concentration of the enzyme. Under such conditions classical enzyme kinetics can be used to determine a rate constant ( $K_m$ ) and a velocity ( $V_{max}$ ) of the reaction.

Kinetic studies are useful for mechanistic studies; they are also powerful tools for  
20 evaluating inhibitors (see below). Standard texts directed at those skilled in the art of enzyme kinetics such as Segel, I.H., *Enzyme Kinetics : Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems* (1993, Wiley-Interscience, ISBN 0471303097) provide complete guidance to establishing these parameters and demonstrate the use, for example, of Lineweaver-Burke plots as graphical tools to  
25 simplify the determination of the kinetic parameters.

High throughput screening systems are known in the art. Such systems often involve the use of multiwell plates to increase the number of assays conducted simultaneously from a few to a hundred, a few hundred or even a few thousand.

Presently preferred high throughput screening adaptions of the methods of the present

5 invention provide capability of screening about one hundred to about one or more thousand assays in a short time. Presently preferred high throughput screening systems include robotic components for example for sample handling, dispensing, reagent addition, and other functions to improve accuracy and eliminate the labor intensive aspects of large numbers of assays. Detection systems for high throughput

10 screening programs are known to those of ordinary skill in the art. Preferred detection systems include, but are not limited to, scintillation counting (including, for example, solid and liquid scintillation for counting gamma or beta particles, or luminescent samples, filter counting, Cerenkov counting, and scintillating microplate counting), fluorescence detection (including, for example, intensity, fluorescence polarization, time-resolved fluorescence, fluorescence resonance energy transfer (FRET)),

15 luminescence, and absorbance.

In a presently preferred embodiment, to achieve high-throughput screening, samples are placed on a multicontainer carrier or platform. A multicontainer carrier facilitates measuring reactions of a plurality of candidate compounds simultaneously.

20 For illustration purposes, but not by way of limitation, a multi-well microplate, such as a 96 or a 384 well microplate, that can accommodate 96 or 384 different test reactions, is used as the carrier. Such multi-well microplates, and methods for their use in numerous assays, are both known in the art and commercially available through sources such as Sigma Chemical Co., BIOCHEMICAL ORGANIC COMPOUND AND

25 DIAGNOSTIC REAGENTS, 2002, pages 2495-2511.

The methods of the present invention are adaptable to miniaturization techniques. Assays for purposes of high throughput screening are often conducted in small volumes. Procedures are currently known to those of skill in the art of reducing volumes of assays in a variety of ways. Microfluidics and microcapillary 5 methodologies now enable assays to be performed down to nanoliter quantities. It is to be understood that the basic principles of the methods and assays apply notwithstanding the volume of the assay, or the manner in which the materials are measured or transported.

The process of determining incubation conditions is routine in the art. 10 Preferred incubation conditions relate, for example, to enzyme stability. Temperature optimums are routine to determine given the specification of the assay and should be determined for a given enzyme and substrate combination for optimum results. Times and other conditions for incubation involve likewise routine determinations. Preference is given to those conditions which result in linearity of the assay. 15 Presently preferred temperatures and times include room temperature for 1 hour, or 37 °C for 30 min, using FAAH from a variety of sources and using anandamide as a substrate. Standard texts directed at those skilled in the art of enzyme assays such as Segel, *supra*, provide complete guidance to optimizing assays, including the incubation conditions. Further characterization of the preferred embodiments is 20 provided in the working examples.

The methods also comprise a step wherein the incubated reaction mixture is contacted with a selective binding material. It is important to note that the selective binding material preferred for this assay may vary with the substrate selected. The selective binding materials comprise materials which can readily be separated from 25 the bulk reaction mixture by separation techniques which are known in the art.

Effective separations can be based on differences in particle size, density, composition and magnetic susceptibility. Material is separated from a reaction mixture by, for example, gravity settling, filtration (including, for example, membrane separations), centrifugation, A presently preferred method of contacting the incubated 5 reaction mixture with a selective binding material comprises activated charcoal.

Where the substrate is anandamide, for example, activated charcoal binds, through adsorption, the substrate and one of the hydrolysis products, arachidonic acid. The other hydrolysis product, ethanolamine, does not adsorb to the activated charcoal. For preferred embodiments, the anandamide substrate is labeled on the ethanolamine 10 moiety. The FAAH hydrolyzes the labeled anandamide into labeled ethanolamine and unlabeled arachidonic acid. After adsorption of the labeled substrate and the unlabeled arachidonic acid to the charcoal, the labeled ethanolamine in solution can be separated from the bound labeled substrate through a simple filtration step. This facilitates the measurement of product without interference from substrate. By 15 removing some compounds through the binding process, the sample is less likely to interfere, for example by quenching, with the measurement of the labeled product. Existing technology has already been adapted for filtering large numbers of samples simultaneously, for example in multiwell filters. This attribute also is adaptable therefore to high throughput screening programs.

20 Although it is often preferred to measure the formation of product in the methods of this invention, assay conditions and selective binding material may be selected wherein the disappearance of substrate is measured. This indirect method is adaptable particularly where a partially purified or substantially purified enzyme is used, or where it is known that there is only one route by which substrate disappears 25 from the reaction mixture. It is also preferred to measure substrate disappearance

wherein a selective binding material which binds the substrate is not readily available. This can be useful in particular in embodiments where the substrate cannot practically be bound to effect its separation from free hydrolysis product but where the hydrolysis product can be more readily bound to effectively separate it from the 5 free labeled substrate. This gives a practitioner the flexibility to choose from a broader range of selective binding materials.

The determination of the amount of labeled substrate hydrolyzed or the labeled hydrolysis product formed is preferably a direct method of quantitating the amount of label present. As discussed above, a variety of detection techniques are 10 suitable for the present invention, and an appropriate detection method relates to the properties of the label present on the substrate or the product. Presently preferred for use with the methods of the invention are radioisotopically labeled substrates and fluorescently labeled substrates, quantified respectively by scintillation counting and fluorescence detection, respectively. In one preferred embodiment, the substrate is 15  $^3\text{H}$ - anandamide, the detection is of the product,  $^3\text{H}$ -ethanolamine, formed, and the detection is with a liquid scintillation counting plate reader from the filtrate of an assay conducted in a multiwell plate.

In another aspect of the invention, methods are provided for identifying 20 modulators of fatty acid amide hydrolase. The methods comprise comparing the activity of fatty acid amide hydrolase as assayed by the method as described herein above, in the presence and in the absence of a test compound added to the reaction mixture; a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

In preferred embodiments, the modulator to be identified is part of compound 25 library, for example, a library of compounds formed by combinatorial chemistry, or a

library of related compounds identified of synthesized as part of a research program.

The putative modulators (i.e the compounds to be tested, test compounds) are preferably a small molecule with properties that would allow it to have utility for pharmaceutical compositions. Preferred modulators have low nonspecific toxicity, 5 and high specificity for modulating FAAH.

Modulators include inhibitors of FAAH activity and activators of FAAH.

Assay parameters such as concentration of substrate, incubation conditions, and concentration of compounds to be tested may be varied to more fully appreciate the modulation effects of a test compound.

10 Preferred modulators that are inhibitors can be identified by their ability to decrease the activity of FAAH relative to that of a control reaction mixture lacking the test compound. Preferably, reaction volumes are maintained constant by adjusting the volume to compensate for the addition of a test compound where the addition of a test compound alters the reaction volume. Most preferably any difference in volume is 15 compensated for by a corresponding addition of a volume, equal to the difference, of the vehicle in which the test compounds are dissolved.

In one aspect of the invention, the modulator identified is an inhibitor of the FAAH activity. Enzyme inhibitors include reversible and irreversible inhibitors.

Preferred inhibitors in some embodiments are reversible inhibitors. Reversible 20 inhibitors of FAAH include competitive inhibitors, which raise the apparent  $K_m$  of the reaction, noncompetitive inhibitors, which reduce the  $V_{max}$  of the enzyme, and inhibitors which affect both  $K_m$  and  $V_{max}$ , namely, mixed inhibitors and uncompetitive inhibitors. The type of inhibitor identified in screens can be determined through the use of kinetic assay studies according to the methods of the present invention. For the 25 purposes of the present invention, however, any compound which decreases the

apparent activity of the enzyme is considered a modulator of the inhibitor type. In other preferred embodiments inhibiting modulators include irreversible inhibitors as well as noncompetitive inhibitors, whose action may be irreversible.

In preferred embodiments the test compound inhibits the FAAH reproducibly, 5 as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, the test compound inhibits fatty acid amide hydrolase activity about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 10 or 90%, or about 95% or more, or up to 100%. In other preferred embodiments, the inhibitor statistically significantly increases the apparent  $K_m$  or decreases the  $V_{max}$  of the reaction.

In another aspect of the invention, the test compound increases fatty acid amide hydrolase activity. Various types of enzyme activators are known to those of 15 skill in the art. Some activators are known to activate enzyme reactions by increasing the velocity of the reaction, others are known to alter the equilibrium attained. Activators that combine reversibly with enzyme reaction components (for example, the enzyme, the substrate, or enzyme-substrate or enzyme-product intermediates) to increase the velocity of the reaction are presently preferred. Nonspecific activators 20 may also increase the reaction rate. For purposes of the present invention, any compound that increases the apparent activity of the enzyme is considered a modulator of the activator type. For example many enzymes are known to have increased activity in the presence of certain anions. Other enzymes, in particular those acting on water-insoluble and charge-neutral molecules, are activated by

negatively charged lipophilic molecules. Some membrane bound enzymes are known to be activated, for example, by specific phospholipids.

In preferred embodiments the test compound activates the FAAH reproducibly, as determined by a statistically significant difference by an appropriate 5 statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, fatty acid amide hydrolase activity is increased about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or about 95% or more, or up to 100%. In other embodiments, activation is 10- 10 30%, 30-50%, 50-70%, 70-90%, 90-110%. In some embodiments, the activator increases FAAH activity 100-300%, 300-500%, 500-700%, or 700-900% or more.

In certain preferred embodiments of the methods of the invention, the fatty acid amide hydrolase is a crude cell lysate or a cell homogenate. In some 15 embodiments the FAAH is isolated partially or substantially from cells. In other embodiments, the fatty acid amide hydrolase is recombinantly produced. The fatty acid amide hydrolase may be from any biological source including mammalian fatty acid amide hydrolases from such animals as pigs, rodents (including rats and mice), and humans, or it may be recombinant FAAH produced in any organism known to be useful for the production of recombinant proteins. Synthetic FAAH based on a 20 particular known amino acid sequence, or on a consensus or combination of any number of sequences that result in an active FAAH is also contemplated for use herein.

Examples of known amino acid sequences of fatty acid amide hydrolases from various biological sources include, for example, SEQ ID NOS: 2, 4, 6, and 8. 25 Examples of known nucleic acid sequences encoding fatty acid amide hydrolases

include SEQ ID NOS:1, 3, 5 and 7. Persons of ordinary skill in the art will recognize that such sequences and the modifications thereof which retain activity, can be used in accordance with the techniques found in references such as those provided above to generate, for example, biological FAAH, recombinant FAAH, overproduced FAAH, 5 or genetically modified FAAH. It is contemplated herein that any form of FAAH is adapted for assay with the methods of the present invention.

In a preferred embodiment the assay is used to measure the activity and identify modulators of FAAH with altered amino acid sequences. Such altered FAAH can result from mutations in the genes which encode FAAH enzymes. In one 10 embodiment, the assay is used to study the activity of, and identify modulators of, altered FAAH in connection with cannabis abuse. For example, a recent paper by Sipe *et al.* (PNAS 99:8394-8398, 2002) describes a strong association between the substitution of Thr for Pro at position 129, and substance abuse in humans. The use 15 of the assay of the present invention may help identify FAAH from humans with higher specific activities or higher levels of net activity, thereby resulting in reduced concentrations of endocannabinoids in the brain, thereby leading to a tendency to seek external cannabinoids to compensate.

In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample 20 containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the 25 incubated reaction mixture with a selective binding material; wherein the selective

binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

10        Preferably, the fatty acid amide hydrolase activity from a sample of fluid or tissue originating from the patient is measured. Presently preferred are blood, lymph or tissue samples. In particularly preferred embodiments, the sample is from lymphocytes from the patient. In preferred embodiments, where the sample is from a woman, the results enable a physician to screen pregnant women for risk of miscarriage (spontaneous abortion) or to screen women seeking fertility treatment for risk of failure of *in vitro* fertilization procedures. In preferred embodiments, results from the patient's sample are compared to results from samples of normal individuals, particularly those comparably positioned in terms of demographic criteria. Results of the assays of the present method may be used to determine either or both of altered specific activity (FAAH activity per unit of FAAH mass) or altered total FAAH activity (net amount of product formed per time). For example, increases in activity can be due to increases in specific activity of the FAAH, for example by alteration of the active site via amino acid alteration, gene mutation and the like, or through alteration of the total amount of FAAH protein present, without a change in the specific activity.

15

20

25

In the methods of the invention, the fatty acid amide hydrolase may be substantially purified from the lymphocyte cell lysate. FAAH may be derived from any source, such that the FAAH retains the potential for FAAH activity. For example, FAAH may be purified from cells expressing FAAH, FAAH may be 5 produced in a recombinant system, including, but not limited to bacterial cells, yeast cells, insect cells, and mammalian cells. FAAH may be derived from any organism that produces FAAH. For example, FAAH may be derived from mammalian cells such as human cells, rodent cells (e.g., mouse and rat cells), or from any other organism that produces FAAH that has FAAH activity. Recombinant FAAH may be 10 produced using techniques known in the art with any nucleic acid sequence encoding FAAH. Examples of cloned FAAHs include various mammalian FAAH such as, pig FAAH, rodent FAAH (e.g., mouse FAAH and rat FAAH), and human FAAH. DNA sequences encoding FAAH and polypeptide sequences of various FAAHs are included in the appended Sequence Listing.

15       FAAH may be purified by standard methods in the art. The FAAH preparation may be in association with cell membranes or artificial membranes, or may be substantially free of cellular material.

Throughout the specification, reference is made to certain publications and 20 patents. The entireties of each of these references is incorporated herein and forms a part of this disclosure.

**EXAMPLES****Example 1**

Radiolabeled anandamide [ $1-^3\text{H}$ -ethanolamine] was obtained from American Radiolabeled Chemicals (10-20 Ci/mmol, catalog number ARC-626; St. Louis, Missouri, USA). Anandamide [arachidonyl-5,6,8,9,11,12,14,15- $^3\text{H}$ ] was obtained from Perkin Elmer (160-240 Ci/mmol, catalog number NET-1073, Boston, Massachusetts, USA), as was radiolabeled arachidonic acid [5,6,8,9,11,12,14,15- $^3\text{H}$  (N)] (180-240 Ci/mmol, catalog number NET298Z). Radiolabeled ethanolamine ([2- $^{14}\text{C}$ ]Ethan-1-ol-2-amine hydrochloride) was purchased from Amersham Pharmacia Biotech (55 mCi/mmol, catalog number CFA329). Methyl arachidonyl fluorophosphate (MAFP) and oleyl trifluoromethyl ketone (OTFMK) were obtained from Cayman Chemical, (Catalog number 70660 and 6260, respectively; Ann Arbor, Michigan, USA). Activated charcoal was from Aldrich Chemical, Milwaukee, USA. Arachidonic acid, anandamide, oleic acid, oleamide, phenylmethylsulfonyl fluoride and  $\text{CuSO}_4$  were from Sigma, St. Louis, Missouri, USA.

T84 human colorectal carcinoma cells (catalog number CCL-248, American Tissue Culture Collection, Manassas, Virginia, USA) were identified as expressing human FAAH based on gene expression profiling of cell lines using DNA microchips (not shown). The cells were cultured in a 1:1 mixture of Ham's F-12 media and 20 Dulbecco's Modified Eagle Medium (Invitrogen) with 5 % fetal bovine serum (HyClone), 50U/ml penicillin and 50 $\mu\text{g}$ /ml streptomycin (Invitrogen). The cells were harvested by scraping into PBS and pelleted in a clinical centrifuge at 1000 rpm. The resulting pellets were then stored at -80°C until needed.

T84 frozen pellets were homogenized in FAAH assay buffer (125mM Tris, 25 1mM EDTA, 0.2% Glycerol, 0.02% Triton X-100, 0.4mM Hepes, pH 9) (Boger *et al.*

(2000) *Proc. Natl. Acad. Sci. USA* 97:5044-5049) and diluted to a final protein concentration of 70  $\mu$ g/ml. Unless otherwise indicated, the assay mixture consisted of 50  $\mu$ l of the cell homogenate, 10  $\mu$ l of the appropriate inhibitor, and 40  $\mu$ l of 40 nM  $^3$ H-AEA, added last, for a final tracer concentration of 16 nM. The reactions were 5 originally done at 37°C for 30 min; but subsequent experiments indicated that the enzyme displayed good activity at room temperature, and experiments were performed at room temperature for 60 minutes unless otherwise indicated.

During the one hour incubation, 96-well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, Massachusetts, USA) were loaded with 10 25  $\mu$ l activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100  $\mu$ l methanol. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100  $\mu$ l MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, Connecticut, USA). After the one hour incubation, 60  $\mu$ l of the reaction mix was transferred to the 15 charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2,000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at room temperature for 1 hour before counting on a Hewlett 20 Packard TopCount. For determination of  $K_m$  values, 1  $\mu$ M  $^3$ H-AEA was combined with 30  $\mu$ M unlabeled AEA and serial 2-fold dilutions were made.

Uncleaved  $^3$ H-anandamide, as well as the unlabeled arachidonic acid, is absorbed by the charcoal. In contrast, the labeled  $^3$ H- ethanolamine flows through the charcoal mini-columns into 96 well counting plates when a vacuum or centrifugation

is applied. The 96 well plates can then be read on a Hewlett Packard TopCount (Fig. 2.)

5 ***Charcoal selectively binds anandamide and arachidonic acid, but not ethanolamine:***

Four different radioactive tracers were used to explore the binding characteristics of the charcoal used in the assay: two tritiated forms of anandamide (labeled either on the ethanolamine moiety; anandamide [1-<sup>3</sup>H-ethanolamine], or on the arachidonic acid moiety; arachidonic acid [5,6,8,9,11,12,14,15-<sup>3</sup>H (N)] ), as well 10 as tritiated arachidonic acid, and <sup>14</sup>C-labeled ethanolamine. Specific amounts of these tracers were incubated with membrane preparations, added to the pre-washed charcoal and recovered by centrifugation, as described in the methods. The recovered radioactivity was counted and expressed as percentage of the amount added. As shown in Fig. 3, when no membranes were present, *i.e.*, there was no FAAH-mediated 15 conversion of anandamide to arachidonic acid plus ethanolamine, neither of the two labeled forms of anandamide could be detected in the flow-through, indicating that the tracers were bound to the charcoal. Tritiated arachidonic acid was also absorbed onto the charcoal and could not be detected in the flowthrough. Of the four tracers used, only the <sup>14</sup>C-ethanolamine could be recovered.

20 It is known that HeLa cells, a human carcinoma cell line, do not express FAAH (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). Therefore, this cell line was used as a negative control, and to investigate the possible contribution of non-FAAH enzymes to the hydrolysis of anandamide. There was essentially no recovery of radioactivity after incubation of <sup>3</sup>H-anandamide with HeLa cell membranes, 25 confirming the absence of FAAH (Fig. 3).

When the tracers were incubated with membranes prepared from mouse liver or T84 cells, good recovery of radioactivity was found for the anandamide labeled on the N-terminus of the amide ( $^3\text{H}$ -ethanolamine), but not for the anandamide carrying the tritium label on the hydrocarbon chain of the fatty acid ( $^3\text{H}$ -AA). All experiments 5 consistently showed that anandamide and arachidonic acid, in contrast to ethanolamine, were absorbed onto the charcoal column. Therefore, when radiolabeled anandamide is incubated with a cell lysate containing FAAH the radioactivity recovered in the flow-through must be attributed to the radiolabeled ethanolamine. This experiment indicates that it is possible to separate anandamide and 10 ethanolamine using charcoal. Other products, such as SAX and C18 resin were also tested, but were less effective (not shown).

*Characterization of the FAAH assay:*

FAAH activity is found in a large variety of cells. In rodents, the liver, followed by the brain, seems to have the highest expression of FAAH, whereas in 15 humans, the expression is highest in the pancreas and brain, but lower in the liver (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). The expression of human FAAH mRNA in T84 cells was found by expression profiling using DNA microarrays (not shown) and confirmed by subsequent experiments.

The signal output of the assay was determined to be linear in the range of 20 0.42-3.5  $\mu\text{g}/\text{well}$  T84 membrane. Since an embodiment of the invention is a HTS-compatible assay, it was verified that the reaction was linear over more than 1 hour at the amount of protein used. As shown in Figure 4 A, the rate of the reaction at room temperature was linear over a period of 90 minutes when 3.5  $\mu\text{g}/\text{well}$  protein was used. This experiment was performed both at room temperature and at 37°C, with the 25 enzyme being slightly more active at the higher temperature, as expected. For the

performance of HTS assays, an incubation period of 1 hour at room temperature and a protein amount of 3.5  $\mu$ g/ well was chosen based on these results.

***Kinetic analysis of FAAH activity:***

Kinetic analyses of the hydrolysis of anandamide by FAAH in T84 human 5 colorectal carcinoma cells demonstrated a  $K_m$  of  $1.1 \pm 0.17 \mu\text{M}$ . (Fig. 4 B). This is close to the value that has been reported for human brain (2  $\mu\text{M}$ , see Maccarrone *et al.* (Maccarrone *et al.* (1999) *Anal. Biochem.* 267:314-318)). Overall, the reported  $K_m$  values in the literature for FAAH reactions range widely, from 0.8 to 80  $\mu\text{M}$ , depending on the tissue, species and method used (Fowler *et al.* (2001) *Biochem. 10 Pharmacol.* 62:517-526). For instance, Desarnaud *et al.* (Desarnaud *et al.* (1995) *J. Biol. Chem.* 270, 6030-6035) found a  $K_m$  of 12.7  $\mu\text{M}$  using rat brain microsomes. In the N18 mouse neuroblastoma cell line, the  $K_m$  was determined to be 9.0  $\mu\text{M}$  (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86). Apart from species differences, the variability in these values has been ascribed to the observation that both the substrate 15 and product of this enzyme can form micelles, which may affect the enzyme activity (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526).

***Validation of the FAAH assay using reference compounds:***

Several of the FAAH inhibitors that have been described in the literature were tested in the assay to validate its ability to identify inhibitors. Of the inhibitors that 20 are commercially available, methyl arachidonyl fluorophosphate (MAFP), which is also an inhibitor of cytosolic phospholipase A<sub>2</sub>, is the most potent, with reported IC<sub>50</sub> values of 1-3 nM (Ueda *et al.* (2000) *Chem. Phys. Lipids* 108, 107-121; Deutsch *et al.* (1997) *Biochem. Pharmacol.* 53, 255-260). Its potency as an inhibitor of FAAH was confirmed with the determination of an IC<sub>50</sub> value of 0.8 nM.

Oleyl trifluoromethyl ketone, a transition-state inhibitor, has also been reported to be a potent inhibitor of FAAH, with an IC<sub>50</sub> of 73.3 nM in the studies here presented, it was in the same range as the IC<sub>50</sub> values of 28 - 41 nM found by Tiger *et al.* (2000; *Biochem. Pharmacol.* 59, 647-653).

5       Phenylmethanesulfonyl fluoride, an inhibitor of serine proteases, was shown to be an inhibitor of FAAH, although with a low potency. Its pIC<sub>50</sub> for the inhibition of rat brain FAAH in another group was between 5.92 and 4.16, depending on the pH (Holt *et al.* (2001) *Br. J. Pharmacol.* 133, 513-520). At a concentration of 100  $\mu$ M, it abolished anandamide hydrolysis in N18 mouse neuroblastoma cells (Maurelli *et al.* 10 (1995) *FEBS Lett.* 377, 82-86). It was used at a concentration of 1.5 mM by Deutsch *et al.* (1993; *Biochem. Pharmacol.* 46, 791-796) to block FAAH activity in neuroblastoma and glial cells. At 25  $\mu$ M, it inhibited the hydrolysis of rat brain microsomal anandamide by 48 % (Desarnaud *et al.* (1995) *J. Biol. Chem.*, 270, 6030-6035). The IC<sub>50</sub> value (16  $\mu$ M) obtained in this work thus corresponds well to the 15 numbers reported in the literature.

Finally, product inhibition was tested by using the FAAH products oleic acid and arachidonic acid. Maurelli *et al.* (1995; *FEBS Lett.* 377, 82-86) found that 100  $\mu$ M anandamide abolished the activity of FAAH. In this work, these compounds inhibited FAAH activity with IC<sub>50</sub> values in the low micromolar range (Table 1).

20       These results confirm that the assay provides a robust method for the evaluation of FAAH activity. The assay was successfully validated using reference inhibitors. As the assay may be performed simultaneously in multiple reactions, such as in a 96 well plate, for example, the assay is adaptable for high-throughput screening of compound collections as well as natural product or combinatorial 25 libraries.

Table 1. Activity of known FAAH inhibitors in T84 membranes

COMPOUND	IC <sub>50</sub> (nM)	Literature (ref)
Methyl arachidonyl fluorophosphate	0.8 ± 0.7	2.5 <sup>(1)</sup> 1-3 <sup>(2)</sup>
Oleyl trifluoromethyl ketone	73.3 ± 19.8	39 <sup>(3)</sup> 24-41 <sup>(4)</sup>
Phenylmethylsulfonyl fluoride	15978 ± 8863	1200-69000 <sup>(5)</sup>
Arachidonic acid	931.4 ± 255.4	-
Oleic acid	1936 ± 401	-

The average ± S.E. of values obtained in 2-5 experiments, each done in triplicate, is given. The numbers in the column on the right refer to literature data. References : (1) : Deutsch *et al.* Biochem. Pharmacol. 1997, 53: 255-260. (2) : Ueda *et al.* Chem. Phys. Lipids 2000, 108 : 107-121. (3) Fowler *et al.* Br. J. Pharmacol. 2000, 131: 498-504. (4) Tiger *et al.* Biochem. Pharmacol. 2000, 59:647-653. (5) Holt *et al.* Br. J. Pharmacol. 2001, 133: 513-520.

The foregoing description, examples and accompanying figures generally describe the invention. The description is for purposes of providing illustrations; the present invention is not to be limited by the specific embodiments described herein. One of skill in the art will appreciate that various modifications of the invention may be made in addition to those described herein. Such modifications are intended to fall within the scope of the appended claims.

## Pig FAAH Nucleic Acid Sequence (SEQ ID NO:1)

cggtcctcg gg tggagatca tggtcagga agaactgtgg gctgcgttct  
 ccggccctc cgggttgc ctggctgct gcttggtgc agcggccttgc  
 gcccgcgtt gttccagtcg ccggatggcg cggggcgcgg cggcccggc  
 ggcacagagg cagcaagcgg ccctggagac catggacaag gccggcgcagc  
 gcttccggct ccagaacccc gatctggact cggagatgct gctggccctg  
 ccactgcctc agctggtaca gaaggtacga agtggggagc tgcgtccaga  
 ggctgtgctc ttttccattc tgcaaaaaggc ctgggaagtg aacagaggga  
 ccaactgcgt gaccacctac ctggcagact gtgaggctca gctgtgccag  
 ggcgcggc agggcctgtc ctacgggtgc cccgtcagcc tcaaggagtg  
 cttagctgc aaggccatg actccacgt gggcttgagc cggaaaccagg  
 ggacaccaggc agaatgtgac tgcgtggtgg tgcaggtgct gaaactgcag  
 ggtgctgtgc ttccgtgca caccaacgtc ccccaagtcca tggtcagcta  
 tgactgcagt aacccctct ttggccagac caccaaccca tggatgtcgt  
 ccaagagccc gggcggtcc tcgggaggtg agggggccct cattgtctgc  
 ggaggctccc cactgggctt aggcacccgac atcggggca gcatccgctt  
 tccctccgcc ttctgtggca tctgccccat caaaccacg gggaaaccgca  
 tcagcaagag tggctctgaag ggctctgtct atggacaggt agcagtgcag  
 ctctcagtgg gccccatggc gggggacgtg gagagcctgg ccctgtgcct  
 gctgtgcgtg ctgtgcgaag acatgttccg cctggacccc acgggtgcctc  
 ccctgcctt caacgaggag gtctacgcaa gctctcgcc cctgcgtgtc  
 gggtattatg agaccgacaa ctacaccatg cccacggcgg ccatgaggcg  
 ggcctgctg gagaccaagc ggagccttga ggctgcggc cacacgctga  
 ttcccttcctt gcccggcaac atacccacg ctctggaggc cctgtcaacg  
 ggcggctct tcagtgtatgg tggaaagagg ttgctacaga acttcgaagg  
 cgattacgtg gactcctgct tagggacact gatctcaatt ctgaggctgc  
 ccaaattggct taaaggactg ctggcttca tgctgaggcc tctgctccca  
 aggttggcag gctttctcag cagcctgagg cctcggtcgg ctggaaagct  
 ctggaaactg cagcacgaga ttgagatgta cctgtactcc gtgattgccc  
 agtggcgagc gctggacccg gatgtggtgc taaccccat gctgagccct  
 gcccctagact tgaatgcccc aggaaggcc acaggggccg tcagctacac  
 gctgctctac aactgcctgg acttccccgc ggggggtggc cctgtcacca  
 cggtaactgc cgaggacgag gcccagatgg agcattacaa gggctacttt  
 gggggacattt gggacaaggt ggtcagaag gccatgaaga ggagcgtgg  
 gctgcctgtg gccgtcgt gttggctct gcccggcag gaggagctgt  
 gtttgcgggtt catgcggag gtggagcgtc tgatggctcc tggggcggcag  
 ccctcctgac cgtgcggcgc ccggcccccc aggacctgag acccaactgga  
 tccgcggccca gcgagtcag gacacaactg ccaccgtca agaaaatgtt  
 caacccctcagg cagaggcttc cgggtctctc cccctcgccc ctgccagaag  
 cccagaacca ctgagtcgtt accttgcgtt tccctggc cctgtctgc  
 cctgaccccg ccaatgtggc agcttagtggg tatgacatgg caaaggcccc  
 ccaaccgtca aaaaccgtt cctggcttcc atacttctg gcagtcgttg  
 ttagggcagt ggggggttgg gacctgacact tctggaaaccc gactccagcc  
 atgtccgtct cgtgcgtcag aagcttctct ggtcctcgct actcacggc  
 agacacccggc ttctccgagt gggcccttgc gcccaggact tcacccccc  
 gccccccagcc taagccctac tttgcggagc attgtttctt ctcctggccct  
 ctgctgaggc tgccctttct gctcctctac cattaaatcc tttgaggccc

## Pig FAAH Amino Acid Sequence (SEQ ID NO:2)

MVQEELWAAF SGPSGVALAC CLVAAALALR WSSRRMARGA AARARQRQQA  
 ALETMDKAAQ RFRLQNPDLQ SEMLLALPLP QLVQKVRSGE LSPEAVLFSY  
 LQKAWEVNRG TNCVTTYLAD CEAQLCQAPG QGLLYGVPVS LKECFSCKGH  
 DSTLGLSRNQ GTPAECDCVV QVVLKLQGAV PFVHTNVPQS MFSDYDCSNPL  
 FGQTTNPWMS SKSPGGSSGG EGALIAAGGS PLGLGTDIGG SIRFPSAFCG  
 ICGIKPTGNR ISKSGLKGSV YGQVAVQLSV GPMARDVESL ALCLRALLCE  
 DMFRLDPTVP PLPFNEEVYA SSRPLRVGYY ETDNYTMPTP AMRRALLETK  
 RSLEAAAGHTL IPFLPANIPH ALEALSTGGL FSDGGKRLLQ NFEQDYVDSC  
 LGDLISILRL PKWLKGLLAF MLRPLLPRLA GFLSSLRPRS AGKLWELQHE  
 IEMYRHSVIA QWRALDLDVV LTPMLSPALD LNAPGKATGA VSYTLLYNCL  
 DFPAGVVVPVT TVTAEDEAQMI EHYKGYFGDI WDKVVQKAMK RSVGLPVAVQ  
 CVALPWQEEL CLRFMREVER LMAPGRQPS

## Mouse FAAH Nucleic Acid Sequence (SEQ ID NO:3)

atggtgctga gcgaagtgtg gaccgcgctg tctggactct ccggggtttg  
 cctagcctgc agcttgctgt cggcggcggt ggtcctgcga tggaccagga  
 gccagaccgc cccggggcgcg gtgaccaggg cgccggcagaa gcagcgagcc  
 ggcctggaga ccatggacaa ggcgggtgcag cgcttccggc tgcagaatcc  
 tgacctggat tcagaggcct tgctggctct gcccctgctc caactggtag  
 agaagttaca gagtggggaa ctgtccccag aagctgtgct ctttacctac  
 ctggggaaagg cctgggaagt gaacaaaggg accaactgtg tgacctccta  
 tctgactgac tgtgagactc agctgtccca ggccccacgg cagggcctgc  
 tctatggcgt ccccgtgagc ctcagaagaa gttcagacta caagggccat  
 gttccacac tgggcttaag tttgaacgag ggtgtgacat cggagagtga  
 ctgtgtggtg gtgcaggtac tgaagctgca gggagctgtg cccttgc  
 acaccaacgt ccccccagtcc atgtaagct atgactgcg taacccccc  
 tttggccaga ccatgaaccc gtgaaagccc tccaagagtc caggaggc  
 ctcagggggt gagggggctc tcattggatc tggaggctcc cctctgggt  
 taggcactga catcgccggc agcatccggt tcccttctgc cttctgtgc  
 atctgtggcc tcaagcctac tggaaaccgc ctcagcaaga gtggcctgaa  
 gagctgtgtt tatggacaga cagcagtgca gttttctgtt ggccccatgg  
 cacggatgt ggatagcctg gcattgtgca tgaaagccct actttgtgag  
 gatttgtcc gttggactc caccatcccc cccttgcct tcagggagga  
 gatctacaga agttctcgac cccttcgtgt gggatactat gaaactgaca  
 actacaccat gcccactcca gccatgagga gggctgtgat ggagaccaag  
 cagagtctcg aggctgtgg ccacacgctg gtcccccct taccaaacaa  
 cataccttat gcccggagg tcctgtcggc aggtgggctg ttcagtgtat  
 gtggctgctc ttttctccaa aacttcaaag ggcactttgt ggatccctgc  
 ttgggggacc tggcttagt gctgaagctg cccaggtgtt taaaaaaact  
 gctgagcttc ctgctgaagc ctctgtttcc tcggctggca gcctttctca  
 acagtagtg tcctcggtca gcccggaaact tggggact gcaactgat  
 attgagatgt atcgccagtc cgtcattgcc cagtggaaagg caatgaactt  
 ggacgtggtg ctaacccca tgctgggtcc tgctctggat ttgaacacac  
 cgggcagagc cacaggggct atcaagctaca ctgttctcta taactgcctg  
 gacttccctg cgggggtgtt gcctgtcacc actgtgaccg ctgaggacga  
 tgcccagatg gaacactaca aaggctactt tggggatatg tgggacaaca  
 ttctgaagaa gggcatgaaa aagggtatag gcctgcctgt gctgtgcag  
 tgcgtggctc tgcctggca ggaagagctg tgtctgcggc tcatgcggga

ggtggaacgg ctgatgaccc ctgaaaagcg gccatcttga
---

Mouse FAAH Amino Acid Sequence (SEQ ID NO:4)
--

MVLSEWWTAL SGLSGVCLAC SLLSAAVVLR WTRSQTARGA VTRRARQKQRA GLETMMDKAVQ RFRLQNPDLQ SEALLALPLL QLVQKLQSGE LSPEAVLFTY LGKAWEVNKG TNCVTSYLTQ CETQLSQAPR QGLLYGVPVS LKECFSYKGH ASTLGLSLNE GVTSESDCCV VQVLKLQGAV PFVHTNVPQS MLSYDCSNPL FGQTMNPWKP SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG ICGLKPTGNR LSKSGLKSCV YGQTAVQLSV GPMARDVDSL ALCMKALLCE DLFRLDSTIP PLPFREEIYR SSRPLRVGYY ETDNYTMPTP AMRRAVMETK QSLEAAAGTL VPFLPNNIPIY ALEVLSAGGL FSDGGCSFLQ NFKGDFVDPC LGDVLVLVQL PRWFKKLLSF LLKPLFPRLA AFLNSMCPRS AEKLWELQHE IEMYRQSVIA QWKAMNLDDVV LTPMLGPALD LNTPGRATGA ISYTVLYNCL DFPAGVVPVT TVTAEDDAQM EHYKGYFGDM WDNILKKGMK KGIGLPVAVQ CVALPWQEEL CLRFMREVER LMTPEKRPS
---

Rat FAAH Nucleic Acid Sequence (SEQ ID NO:5)
--

ggtttgtcg agccgagttc ttcgggtgg cggtcggctg caggagatca tggtgcttag cgaagtgtgg accacgctgt ctggggctc cggggtttgc ctagcctgca gttgttgtc ggcggcggtg gtcctgcgt ggaccggcg ccagaaggcc cggggcgccg cgaccaggcc gcggcagaag cagcgagcca gcctggagac catggacaag gcggtgcagc gttccggct gcagaatcct gacctggact cggaggccctt gctgaccctg cccctactcc aactggtaca gaagttacag agtggagagc tggcccaaga ggctgttgc ttacttacc tggaaaggc ctggaaagtg aacaaaggga ccaactgcgt gacccctat ctgaccgact gtgagactca gctgtcccag gccccacggc agggcctgct ctatgggtc cctgtgagcc tcaaggaatg cttcagctac aaggccacg actccacact gggcttgagc ctgaatgagg gcatgcacat ggaatctgac tgtgttgtgg tgcaagtgtt gaagctgcag ggagctgtgc cctttgtgca taccaatgtc ccccagtcca tggtaagctt tgactgcagt aaccctct ttggccagac catgaaccca tggaaagtctt ccaagagccc aggaggttcc tcaggggtg agggggctct cattggatct ggaggttccc ctctgggtt aggcactgac attggcgca gcatccgggtt cccttctgccc ttctgcggca tctgtggctt caagctact ggcaaccggcc tcagcaagag tggctgaag ggctgtgtct atggacagac ggcagtgcag ctttcttgc gccccatgac ccggatgtg gagagcctgg cgctatgcct gaaagctta ctgtgtgagc acttggtcac ctggaccctt accgtgcctc ctttgcctt cagagaggag gtctatagaa gttctagacc cctgcgtgtg ggttactatg agactgacaa ctataccatg cccagcccaag ctatgaggag ggctctgata gagaccaagc agagacttga ggctgtggc cacacgctga ttcccttctt acccaacaac ataccctacg ccctggaggt cctgtctgca ggcggctgt tcagtgacgg tggcccgagt tttctccaaa acttcaaagg tgactttgt gatccctgt tggagacactt gatcttatt ctgaggctgc ccagctgggtt taaaagactg ctgagcctcc tgctgaagcc tctgtttcct cggctggcag ctttctcaa cagtatgcgt cctcggtcag ctgaaaagct gtggaaactg cagcatgaga ttgagatgta tcgcccgtct gtgattgccc agtggaaagc gatgaacttg gatgtgtgc tgaccccat gttggccct gctctggatt tgaacacacc ggcagagcc acaggggcta tcagctacac cgttctctac aactgcctgg acttccctgc ggggtggc cctgtcacca ctgtgaccgc cgaggacat
---

gcccagatgg aactctacaa aggctacttt gggatatatct gggacatcat  
 cctgaagaag gccatgaaaa atatgttcgg tctgcctgtg gctgtgcagt  
 gcgtggctct gcccggcag gaagagctgt gtctgagggtt catgcggag  
 gtggAACAGC tggatgacccc tcaaaagcag ccacatcgtag ggtcggtcat  
 ccgcccagctc tggaggacat aaggcccatt cgctgtgcac tggatccccca  
 tggatccagg agccaccacc cacgaggaa cgcccagcac agggaaaggagg  
 tggatcacctg ccctccccctg gactcctgcg cccacaacca agtctggacc  
 ttcctccccctg ttatggctca ctttccatcc tgattccctg ctttttatgg  
 cagccagcag gaatgacgtg ggccaaggat caccaacatt caaaaacaat  
 gcgttatct attttctggg tatotccatt agggccctgg gaaccagagt  
 gctggaaagg ctgtccagac cctccagagc tggctgtaac cacatcactc  
 tcctgcctca aaggcctccct agttctgtca cccacaagat agacacaggg  
 acatgtcctt ggcacttgcac tcctgtcctt cttttcttat tcagattgac  
 cccagcctt gatggaccctg cccctgcact tccttcctca gtccacctct  
 ctggcagacac gccccttttta tggctcctctt atttgttggg gagacaagg  
 ttctctcagt agccctggct gtccaggacc tcactctgt aatgaggctg  
 gcttcaact cacaaggctg cctgcctggg tgctggatt aaaggcgtat  
 gcccaccacaa agaaaaaaaaaa aa

Rat FAAH Amino Acid Sequence (SEQ ID NO:6)

MVLSEVWTTL SGVSGVCLAC SLLSAAVVLR WTGRQKARGA ATRARQKQRA  
 SLETMDKAVQ RFRLQNPDLQ SEALLTLPLL QLVQKLQSGE LSPEAVFFTY  
 LGKAWEVNKG TNCVTSYLLD CETQLSQAPR QGLLYGVPVS LKECFSYKGH  
 DSTLGLSLNE GMPSESDCVV VQVILKLQGAV PFVHTNVPQS MLSFDCSNPL  
 FGQTMNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG  
 ICGLKPTGNR LSKSGLKGCV YGQTAQVQLSL GPMARDVESL ALCLKALLCE  
 HLFTLDPPTVPLPFREEVYR SSRPLRVGYY ETDNYTMPSP AMRRALIETK  
 QRLEAAGHTL IPFLPNNIPIY ALEVLSAGGL FSDGGRSFLQ NFKGDFVDP  
 LGDLILILRL PSWFKRLLSL LLKPLFPRLA AFLNSMRPRS AEKLWKLQHE  
 IEMYRQSVIA QWKAMNLSDLV LTPMLGPALD LNTPGRATGA ISYTVLYNCL  
 DFPAGVVPVT TVTAEDDAQM ELYKGYFGDI WDIILKKAMK NSVGLPVAVQ  
 CVALPWQEEL CLRPMREVEQ LMTPQKQPS

Human FAAH Nucleic Acid Sequence (SEQ ID NO:7)

tgccggccgg taggcagcag caggctgaag ggatcatggt gcagtcgg  
 ctgtggccgg cgctgcctgg cgcctccggg gtcgcctgg cctgctgctt  
 cgtggccggc gcccgtggcc tgcgtggc cggcgccgg acggcgccgg  
 gccgcgtggt cccggcgccga cagaagcagc gagcggccct ggagaacatg  
 gacagggccgg cgcagcgctt ccgcctccag aacccagacc tggactcaga  
 ggcgcgtcta gcccgcctt tgccctcagct ggtgcagaag ttacacagta  
 gagagctggc ccctgaggcc gtgtcttca cctatgtggg aaaggcctgg  
 gaagtgaaaca aagggacaa ctgtgtgacc tcctatctgg ctgactgtga  
 gactcagctg ttcagggcc caaggcaggc cctgctctat ggcgtccctg  
 tgagcctcaa ggagtgcctt acctacaagg gcccggactc cacgctggc  
 ttgagcctga atgaagggt gcccggcggag tgccgacagcg tagtggtgca  
 tggctgtgaag ctgcagggtg ccgtgcctt cgtgcacacc aatgttccac  
 agtccatgtt cagctatgac tgcaatgacc ccctcttgg ccagaccgtg  
 aacccatgga agtccctcaa aagcccgagg ggctcctcag ggggtgaagg  
 ggccctcatac gggctctggag gctccccctt gggcttaggc actgatatcg

gaggcagcat ccgcttcccc tcctccttct gcggcatctg cggcctcaag  
 cccacagggc accgcctcag caagagtggc ctgaagggt gtgtctatgg  
 acaggaggca gtgcgtctct ccgtggccc catggccgg gacgtggaga  
 gcctggcaact gtgcctgcga gccctgctgt gcgaggacat gttccgcttgc  
 gaccccaactg tgcctccctt gcccttcaga gaagaggtct acaccagctc  
 tcagccccctg cgtgtgggt actatgagac tgacaactat accatgccct  
 cccccggccat gaggcgggccc gtgctggaga ccaaacagag ccttgaggct  
 gcggggcaca cgctggttcc cttcttgcca agcaacatac cccatgctct  
 ggagaccctg tcaacaggtg ggctttcag tgatggggc cacaccccttcc  
 tacagaactt caaaggtgat ttcgtggacc cctgcctggg ggacctggc  
 tcaattctga agcttccca atggctaaa ggactgctgg ccttcctgg  
 gaagcctctg ctgccaaggc tgtagcttt cctcagcaac atgaagtctc  
 gttcggctgg aaaactctgg gaactgcagc acgagatcga ggtgtaccgc  
 aaaaccgtga ttgcccagtg gaggcgcctg gacctggatg tggtgctgac  
 cccccatgctg gcccctgctc tggacttggaa tgcccccaggc agggccacag  
 gggccgtcag ctacactatg ctgtacaact gcctggactt ccctgcaggg  
 gtgggcctg tcaccacggt gactgctgag gacgaggccc agatggaaaca  
 ttacaggggc tactttgggg atatctggga caagatgctg cagaagggca  
 tgaagaagag tggggggctg ccggtgccg tgcaagtgtg ggctctgccc  
 tggcaagaag agttgtgtct gcggttcatg cgggaggtgg agcgactgat  
 gaccctgaa aagcagtcat cctgatggct ctggctccag aggacctgag  
 actcacactc tctgcagccc agcctagtca gggcacagct gccctgctgc  
 cacagaagg aaatgtcctg catggggcag aggcttccgt gtccctctccc  
 ccaacccct gcaagaagcg ccgactccct gagtctggac ctccatccct  
 gctctggtcc cctctcttcg tcctgatccc tccaccccca tgtggcagcc  
 catgggtatg acataggcca aggcccaact aacagtcaag aaacaaaaaaa  
 aaaaaaaaaaaa aaa

Human FAAH Amino Acid Sequence (SEQ ID NO:8)

MVQYELWAAL PGASGVALAC CFVAAAVALR WSGRRTARGA VVRARQKQRA  
 GLENMDRAAQ RFRLQNPDLD SEALLALPLP QLVQKLHSRE LAPEAVLFTY  
 VGKAWEVNKG TNCVTSYLAQ CETQLSQAPR QGLLYGVPVS LKECFTYKGQ  
 DSTLGLSLNE GVPaecDSVV VHVLKLQGAV PFVHTNVPQS MFSYDCSNPL  
 FGQTVNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSSFCG  
 ICGLKPTGNR LSKSGLKGCV YGQEAVRLSV GPMARDVESL ALCLRALLCE  
 DMFRLDPTVP PLPFREEVYT SSQPLRVGYY ETDNYTMAPSP AMRRAVLETK  
 QSLEAAGHTL VPFLPSNIPH ALETLSTGGL FSDGGHTFLQ NFKGDFVDP  
 LGDLVSLKL PQWLKGLLAF LVKPLLPRLS AFLSNMKSRS AGKLWELQHE  
 IEVYRKTVIA QWRALDLVV LTPMLAPALD LNAPGRATGA VSYTMLYNCL  
 DFPAGVVPVT TVTAEDEAQM EHYRGYFGDI WDKMLQKGMK KSVGLPVAVQ  
 CVALPWQEEL CLRFMREVER LMTPEKQSS

What is claimed is:

1. A method of assaying the activity of a fatty acid amide hydrolase comprising the steps of:
  - combining a sample suspected of containing a fatty acid amide hydrolase, with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture;
  - incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;
  - contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;
  - separating the bound labeled complex from the incubated reaction mixture;and
  - determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.
2. The method of claim 1 wherein the sample comprises biological membranes, lipid bilayers, or micelles.
3. The method of claim 1 wherein the substrate is an endocannabinoid, a fatty acid ethanolamide, a fatty acid primary amide, an endocannabinoid analog, a fatty acid ethanolamide analog, or a fatty acid primary amide analog.
4. The method of claim 1 wherein the substrate is anandamide.

5. The method of claim 1 wherein the substrate is oleamide.
6. The method of claim 1 wherein the substrate is 2-arachidonoylglycerol.
7. The method of claim 1 wherein the substrate is labeled with a radioisotope.
8. The method of claim 7 wherein the radioisotope is <sup>3</sup>H or <sup>14</sup>C.
9. The method of claim 1 wherein the substrate is labeled with a fluorescent label.
10. The method of claim 1 wherein the selective binding material comprises carbon.
11. The method of claim 10 wherein the selective binding material is activated charcoal.
12. The method of claim 11 wherein the activated charcoal comprises a filter.
13. The method of claim 1 wherein the selective binding material binds the labeled substrate but not the labeled product.
14. The method of claim 1 wherein the separating step comprises filtration, gravity settling or centrifugation.

15. The method of claim 1 wherein the determining step is performed via liquid scintillation counting or by measurement of fluorescence energy.

16. The method of claim 1 conducted in a multiwell plate.

17. The method of claim 1 comprising at least a portion of a high throughput screening program.

18. The method of claim 1 wherein the method is conducted in conjunction with a drug discovery effort.

19. A method of identifying a compound that modulates the activity of a fatty acid amide hydrolase comprising the steps of:

comparing the activity of a fatty acid amide hydrolase as assayed by the method of claim 1, in the presence and in the absence of a test compound added to the reaction mixture;

wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

20. The method of claim 19 wherein the test compound is selected from a library of compounds.

21. The method of claim 19 wherein the test compound inhibits the activity of the fatty acid amide hydrolase activity.

22. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 5%.

23. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 20%.

24. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 50%.

25. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 80%.

26. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 95% or more.

27. The method of claim 21 wherein said test compound increases said fatty acid amide hydrolase activity.

28. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 5%.

29. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 30%.

30. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 50%.
31. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 70%.
32. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 100%.
33. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased between about two-fold to about ten-fold.
34. The method of claim 19, which comprises the use of a multi-well plate.
35. The method of claim 19 conducted in a multiwell plate.
36. The method of claim 19 comprising at least a portion of a high throughput screening.
37. The method of claim 19 wherein the method is conducted in conjunction with a drug discovery effort.
38. The method of claim 1 wherein said fatty acid amide hydrolase is a mammalian fatty acid amide hydrolase.

39. The method of claim 38 wherein said fatty acid amide hydrolase is a porcine fatty acid amide hydrolase.

40. The method of claim 38 wherein said fatty acid amide hydrolase is a rodent fatty acid amide hydrolase.

41. The method of claim 38 wherein said fatty acid amide hydrolase is a murine fatty acid amide hydrolase.

42. The method of claim 41 wherein said fatty acid amide hydrolase is a rat fatty acid amide hydrolase.

43. The method of claim 41 wherein said fatty acid amide hydrolase is a mouse fatty acid amide hydrolase.

44. The method of claim 38 wherein said fatty acid amide hydrolase is a human fatty acid amide hydrolase.

45. A method for determining altered fatty acid amide hydrolase activity in a patient comprising:

obtaining a sample containing cells from the patient;  
lysing the cells to form a cell lysate;  
combining the cell lysate with a labeled substrate of fatty acid amide hydrolase, to form a reaction mixture;

incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;

contacting the incubated reaction mixture with a selective binding material, wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;

separating the bound labeled complex from the incubated reaction mixture;

determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and

comparing the activity of the sample from the patient with the activity of a to a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

46. The method of claim 45 wherein said patient is female.

47. The method of claim 46 wherein the female is pregnant or is seeking fertility treatment.

48. The method of claim 45 wherein the sample comprises blood, tissue or body fluid.

49. The method of claim 46 wherein the sample comprises lymphocytes.



50. The method of claim 45 wherein the cells are homogenized.

51. The method of claim 45 wherein the fatty acid amide hydrolase activity present in the cell lysate is partially or substantially purified from the sample.


52. The method of claim 45 wherein the predetermined determined value is from a control assay, a prior or subsequent sample from the patient, a sample from a normal individual, a sample from another patient, a standard FAAH, or a predetermined value.

1/4


Step 1 : incubate  $^3\text{H}$ -anandamide with FAAH-containing membranes



**Step 2 : load on charcoal-filled filterplates**



### Step 3 : centrifuge



Step 4 : add scintillant to flow-through and count

FIG 1

2/4





FIG 2

3/4

**FIG 3**

4/4




FIG 4A




FIG 4B

## SEQUENCE LISTING

<110> Barbier, Ann Johanna  
Wilson, Sandy J. .  
Mazur, Curt

<120> Assay for Determining the Activity of Fatty Acid Amide Hydrolase

<130> PRI0002

<160> 8

<170> PatentIn version 3.1

<210> 1  
<211> 2300  
<212> DNA  
<213> Sus scrofa

<400> 1  
cggtcctcg tggagatca tggtcagga agaactgtgg gtcgcgttcc cggccccctc 60  
cggggttgc ctggcctgct gcttggtggc agcggccttgc cccctgcgtt ggtccagtcg 120  
ccggatggcg cggggcgccgg cgccccgggc gcgacagagg cagcaagccgg ccctggagac 180  
catggacaag cggcgcagc gcttccggct ccagaacccc gatctggact cggagatgct 240  
gctggccctg ccactgcctc agctggtaca gaaggtacga agtggggagc tgcgtccaga 300  
ggctgtgctc tttcctacc tgcaaaaggc ctggaaagtgc aacagaggga ccaactgcgt 360  
gaccacccatc ctggcagact gtgaggctca gctgtgccag gcggccgggc agggcctgct 420  
ctacggtgtc cccgtcagcc tcaaggagtgc ttcaagctgc aaggccatg actccacgct 480  
gggcttgagc cggaaaccagg ggacaccaggc agaatgtgac tgcgtggtgg tgcaggtgct 540  
gaaactgcag ggtgtgtgc ctggcgtgca caccaacgtc ccccaagtccatg tggatgtcgta 600  
tgactgcagt aacccctct ttggccagac cacgaacccca tggatgtcgta ccaagagccc 660  
ggcggtcc tcgggagggtg agggggccctt cattgtgtgc ggaggctccc cactggctt 720  
aggcaccgac atcggggca gcatccgctt tccctccggcc ttctgtggca tctgcggcat 780  
caaaccacg gggaaaccgca tcagcaagag tggctgtgaag ggctctgtct atggacaggt 840  
agcagtgcag ctctcagtgg gccccatggc gcgggacgtg gagagcctgg ccctgtgcct 900  
gcgtgcgcgtc ctgtgcgaag acatgttccgc cttggacccca acgggcgcctc ccctgcctt 960  
caacgaggag gtctacgca gctctcgcc cctgcgtgtc gggtattatg agaccgacaa 1020  
ctacaccatg cccacgcggc ccatgaggcg ggcctgcgtc gagaccaagc ggagccttga 1080  
ggctgcgggc cacacgcgtga ttcccttcct gccggccaac atacccacg ctctggaggc 1140  
cctgtcaacg ggcgggtcttc tcaatgtatgg tggaaagagg ttgctacaga acttcgaagg 1200  
cgattacgtg gactcctgct taggggacct gatctcaatt ctgaggctgc ccaaattggct 1260  
taaaggactg ctggctttca tgctgaggcc tctgcgtccaa aggtggcag gcttctcg 1320  
cagcctgagg cctcggtcggt ctggaaagct ctggaaactg cagcacgaga ttgagatgta 1380  
ccgtcactcc gtgattgccc agtggcgagc gctggacccgt gatgtggtgc taaccccat 1440  
gctgagccct gcccgtact tgaatgcccc aggcaaggcc acagggggccg tcagctacac 1500  
gctgtctac aactgcctgg acttcccccgc ggggggtggtgc cctgtcacca cgggtactgc 1560

cgaggacgag	gcccagatgg	agcattacaa	gggctacttt	ggggacattt	gggacaagg	1620		
ggtgtcagaag	gcccataaga	ggagcgtggg	gctgcctgtg	gccgtgcagt	gtgtggctct	1680		
gcccggcag	gaggagctgt	gtttgcggtt	catgcgggag	gtggagcgcac	tgtatggctcc	1740		
tgggcggcag	ccctcctgac	cgctgcccgc	ccggcccccc	aggacactgag	acccactgga	1800		
tccgcgccc	gcggagtcag	gacacaactg	ccacccgtgca	agaaaatgtt	caacctcagg	1860		
cagaggctc	ccggctctc	cccctcgccc	ctgcccagaag	cccagaacca	ctgagctctgg	1920		
accttgc	tccctggtc	cctgc	cctgc	ccaatgtggc	agctagtgg	1980		
tatgacatgg	caaaggcccc	ccaaacgtca	aaaacgggtt	cctggctcc	atactttctg	2040		
gcagtcgtt	ttagggcagt	gggggttgg	gacctgac	tctggacccc	gactccagcc	2100		
atgtccgtct	cgtgc	aa	gg	actcacggc	agacacccggc	2160		
ttctccgagt	gggccttgca	gcccaggact	tcacccggcc	gccccagcc	taagccctac	2220		
tttgcgagc	attgtcttct	ctc	ctc	ctg	tgccctttct	gctc	ctctac	2280
cat	aaatcc	ttt	gaggccc			2300		

<210> 2  
 <211> 579  
 <212> PRT  
 <213> Sus scrofa

<400> 2

Met Val Gln Glu Glu Leu Trp Ala Ala Phe Ser Gly Pro Ser Gly Val  
 1 5 10 15

Ala Leu Ala Cys Cys Leu Val Ala Ala Leu Ala Leu Arg Trp Ser  
 20 25 30

Ser Arg Arg Met Ala Arg Gly Ala Ala Ala Arg Ala Arg Gln Arg Gln  
 35 40 45

Gln Ala Ala Leu Glu Thr Met Asp Lys Ala Ala Gln Arg Phe Arg Leu  
 50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Met Leu Leu Ala Leu Pro Leu Pro  
 65 70 75 80

Gln Leu Val Gln Lys Val Arg Ser Gly Glu Leu Ser Pro Glu Ala Val  
 85 90 95

Leu Phe Ser Tyr Leu Gln Lys Ala Trp Glu Val Asn Arg Gly Thr Asn  
 100 105 110

Cys Val Thr Thr Tyr Leu Ala Asp Cys Glu Ala Gln Leu Cys Gln Ala  
 115 120 125

Pro Gly Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
 130 135 140

Phe Ser Cys Lys Gly His Asp Ser Thr Leu Gly Leu Ser Arg Asn Gln  
145 150 155 160

Gly Thr Pro Ala Glu Cys Asp Cys Val Val Val Gln Val Leu Lys Leu  
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Thr Asn Pro Trp  
195 200 205

Met Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220

Ile Ala Ala Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Ile Lys Pro  
245 250 255

Thr Gly Asn Arg Ile Ser Lys Ser Gly Leu Lys Gly Ser Val Tyr Gly  
260 265 270

Gln Val Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Asn Glu Glu Val Tyr Ala  
305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Leu Leu Glu Thr Lys Arg Ser  
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Ala Asn Ile  
355 360 365

Pro His Ala Leu Glu Ala Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
370 375 380

Gly Lys Arg Leu Leu Gln Asn Phe Glu Gly Asp Tyr Val Asp Ser Cys  
385 390 395 400

Leu Gly Asp Leu Ile Ser Ile Leu Arg Leu Pro Lys Trp Leu Lys Gly  
405 410 415

Leu Leu Ala Phe Met Leu Arg Pro Leu Leu Pro Arg Leu Ala Gly Phe  
420 425 430

Leu Ser Ser Ile Arg Pro Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg His Ser Val Ile Ala Gln Trp Arg Ala  
 450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ser Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Ala Pro Gly Lys Ala Thr Gly Ala Val Ser Tyr Thr Leu Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Ile Trp Asp Lys Val Val Gln Lys Ala Met Lys Arg Ser Val Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Ala Pro Gly Arg  
 565 570 575

Gln Pro Ser

<210> 3  
 <211> 1740  
 <212> DNA  
 <213> Mouse

<400> 3  
 atggtgctga gcgaagtgtg gaccgcgtg tctggactct cgggggtttg cctagcctgc 60  
 agcttgctgt cggccggcgggt ggtcctgcga tggaccagga gccagaccgc cgggggcgcg 120  
 gtgaccaggg cggggcagaa gcagcgagcc ggctggaga ccatggacaa ggcgggtcag 180  
 cgcttccggc tgcagaatcc tgacctggat tcagaggcct tgctggctct gcccctgctc 240  
 caactggtagc agaagttaca gagtggggaa ctgtccccag aagctgtgct ctttacctac 300  
 ctggggaaagg cctggaaagt gaacaaaggg accaactgtg tgacctccta tctgactgac 360  
 tggtagactc agctgtccca ggccccacgg cagggcctgc tctatggcgt cccctgtgac 420  
 ctcagaaggat gcttcagcta caagggccat gcttccacac tgggcttaag tttgaacgag 480  
 ggtgtgacat cggagaggtga ctgtgtggtg gtgcaggtac tgaagctgca gggagctgtg 540  
 ccctttgtgc acaccaacgt cccccagtcc atgctaagct atgactgcag taacccctc 600  
 tttggccaga ccatgaaccc gtggaagccc tccaagagtc caggaggttc ctcagggggt 660  
 gagggggctc tcattggatc tggaggtcc cctctgggtt taggcactga catcggcggc 720

agcatccggc	tcc <u>cc</u> ttctgc	cttctgtggc	atctgtggcc	tcaaggctac	tgggaaccgc	780
ctcagcaaga	gtggcctgaa	gagctgtgtt	tatggacaga	cagcagtgc	gctttctgtt	840
ggcccccattgg	cacgggatgt	ggatagcctg	gcattgtgc	tgaaagccct	actttgtgag	900
gatttgttcc	gcttggactc	caccatcccc	cccttgcct	tcagggagga	gatctacaga	960
agttctcgac	cccttggtgt	gggatactat	gaaactgaca	actacaccat	gcccactcca	1020
gccatgagga	gggctgtgat	ggagaccaag	cagagtctcg	aggctgtgg	ccacacgctg	1080
gtcccccttct	taccaaacaa	cataccttat	gccctggagg	tcctgtcggc	agggtggctg	1140
ttcagtgatg	gtggctgctc	ttttctccaa	aacttcaaag	gcgactttgt	ggatccctgc	1200
ttgggggacc	tggctttagt	gctgaagctg	cccagggtgt	ttaaaaaact	gctgagcttc	1260
ctgctgaagc	ctctgtttcc	tcggctggca	gccttctca	acagtagtgc	tcctcggtca	1320
gccgaaaagc	tgtgggaaact	gcagcatgag	attgagatgt	atcgccagtc	cgtcatggc	1380
cagtggaaagg	caatgaactt	ggacgtggtg	ctaaccccca	tgctgggtcc	tgctctggat	1440
ttgaacacac	cgggcagagc	cacagggct	atcagctaca	ctgttctcta	taactgcctg	1500
gacttccctg	cgggggtgt	gcctgtcacc	actgtgaccg	ctgaggacga	tgcccagatg	1560
gaacactaca	aaggctactt	tggggatatg	tggacaaca	ttctgaagaa	gggcatgaaa	1620
aagggtata	gcctgcctgt	ggctgtgcag	tgcgtggctc	tgccctggca	ggaagagctg	1680
tgtctgcgg	tcatgcggg	ggtggAACGG	ctgatgaccc	ctgaaaagcg	gccatcttga	1740

<210> 4  
 <211> 579  
 <212> PRT  
 <213> Mouse

<400> 4

Met Val Leu Ser Glu Val Trp Thr Ala Leu Ser Gly Leu Ser Gly Val  
 1 5 10 15

Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
 20 25 30

Arg Ser Gln Thr Ala Arg Gly Ala Val Thr Arg Ala Arg Gln Lys Gln  
 35 40 45

Arg Ala Gly Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
 50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Leu  
 65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
 85 90 95

Leu Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
 100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala

115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140Phe Ser Tyr Lys Gly His Ala Ser Thr Leu Gly Leu Ser Leu Asn Glu  
145 150 155 160Gly Val Thr Ser Glu Ser Asp Cys Val Val Gln Val Leu Lys Leu  
165 170 175Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu  
180 185 190Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp  
195 200 205Lys Pro Ser Lys Ser Pro Gly Gly Ser Ser Gly Glu Gly Ala Leu  
210 215 220Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Ser Cys Val Tyr Gly  
260 265 270Gln Thr Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Asp  
275 280 285Ser Leu Ala Leu Cys Met Lys Ala Leu Leu Cys Glu Asp Leu Phe Arg  
290 295 300Leu Asp Ser Thr Ile Pro Pro Leu Pro Phe Arg Glu Glu Ile Tyr Arg  
305 310 315 320Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335Met Pro Thr Pro Ala Met Arg Arg Ala Val Met Glu Thr Lys Gln Ser  
340 345 350Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Asn Asn Ile  
355 360 365Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly  
370 375 380Gly Cys Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
385 390 395 400

Leu Gly Asp Leu Val Leu Val Leu Lys Leu Pro Arg Trp Phe Lys Lys  
 405 410 415

Leu Leu Ser Phe Leu Lèu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
 420 425 430

Leu Asn Ser Met Cys Pro Arg Ser Ala Glu Lys Leu Trp Glu Leu Gln  
 435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
 450 455 460

Met Asn Leu Asp Val Val Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
 465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
 500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly  
 515 520 525

Asp Met Trp Asp Asn Ile Leu Lys Lys Gly Met Lys Lys Gly Ile Gly  
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
 565 570 575

Arg Pro Ser

<210> 5  
 <211> 2472  
 <212> DNA  
 <213> *rattus rattus*

<400> 5  
 ggttgtgcg agccgagttc tctcggtgg cggcggctg caggagatca tggtgctgag 60  
 cgaagtgtgg accacgctgt ctgggtctc cgggtttgc ctgcctgca gcttgggttc 120  
 ggcggcggtg gtcctgcgtt ggaccggcg ccagaaggcc cggggcgcgg cgaccaggc 180  
 gccggcagaag cagcgagcca gcctggagac catggacaag gccgtgcagc gcttccggct 240  
 gcagaatcct gacctggact cggaggcctt gctgaccctg cccctactcc aactggtaca 300  
 gaagttacag agtggagagc tgcgtccaga ggctgtgttc tttacttacc tggaaaggc 360  
 ctgggaagtg aacaaaggga ccaactgcgt gacccctat ctgaccgact gtgagactca 420  
 gctgtcccaag gccccacggc agggcctgtctatggtgtc cctgtgagcc tcaaggaatg 480  
 cttcagctac aagggccacg actccacact gggcttgagc ctgaatgagg gcatgccatc 540

ggaatctgac	tgtgtgggg	tgcaagtgtt	gaagctgcag	ggagctgtgc	cctttgtca	600
taccaatgtc	ccccagtcca	tgttaagctt	tgactgcagt	aaccctctt	ttggccagac	660
catgaaccca	tggaagtcc	ccaagagccc	aggaggttcc	tcaggggtg	agggggctct	720
cattggatct	ggaggttccc	ctctgggtt	aggcactgac	attggcggca	gcatccggtt	780
cccttctgcc	ttctgcggca	tctgtggct	caagcctact	ggcaaccgcc	tcagcaagag	840
tggcctgaag	ggctgtgtct	atggacagac	ggcagtgcag	ctttctctt	gccccatggc	900
ccggggatgtg	gagagcctgg	cgctatgcct	gaaagctcta	ctgtgtgagc	acttgttcac	960
cttggaccct	accgtgcctc	ccttgcctt	cagagaggag	gtctatagaa	gttctagacc	1020
cctgcgtgtg	gggtactatg	agactgacaa	ctataccatg	cccagcccag	ctatgaggag	1080
ggctctgata	gagaccaagc	agagacttga	ggctgctggc	cacacgctga	ttcccttctt	1140
acccaacaac	ataccctacg	ccctggaggt	cctgtctgcg	ggcggcctgt	tcagtgacgg	1200
tggccgcagt	tttctccaaa	acttcaaagg	tgactttgt	gatccctgct	tgggagacct	1260
gatcttaatt	ctgaggctgc	ccagctggtt	taaaaagactg	ctgagcctcc	tgctgaagcc	1320
tctgtttcct	cggctggcag	ccttctcaa	cagtatgcgt	cctcggcgt	ctgaaaagct	1380
gtggaaaactg	cagcatgaga	ttgagatgta	tcgccagtct	gtgattgccc	agtggaaagc	1440
gatgaacttg	gatgtgctgc	tgacccccc	gttggccct	gctctggatt	tgaacacacc	1500
gggcagagcc	acaggggcta	tcagctacac	cgttctctac	aactgcctgg	acttccctgc	1560
gggggtggtg	cctgtcacca	ctgtgaccgc	cgaggacgat	gcccagatgg	aactctacaa	1620
aggctacttt	ggggatatact	gggacatcat	cctgaagaag	gccatgaaaa	atagtgtcgg	1680
tctgcctgtg	gctgtgcagt	gcgtggctct	gccctggcag	gaagagctgt	gtctgaggtt	1740
catgcgggag	gtggaacagc	tgatgacccc	tcaaaagcag	ccatcgtgag	ggtcgttcat	1800
ccgccagctc	tggaggacct	aaggccatg	cgctgtgcac	tgtagcccc	tgtattcagg	1860
agccaccacc	cacgagggaa	cggccagcac	agggaaagagg	tgtctacctg	ccctccctg	1920
gactcctgca	gccacaacca	agtctggacc	ttcctcccc	ttatggtcta	ctttccatcc	1980
tgattccctg	cttttatgg	cagccagcag	gaatgacgtg	ggccaaggat	caccaacatt	2040
caaaaacaat	gcgttatct	atttctggg	tatctccatt	agggccctgg	gaaccagagt	2100
gctggaaagg	ctgtccagac	cctccagac	tggctgtaac	cacatcactc	tcctgctcca	2160
aaggctccct	agttctgtca	cccacaagat	agacacaggg	acatgtccct	ggcacttgac	2220
tcctgtcctt	ccttcttat	tcagattgac	cccagcctt	atggaccctg	cccctgcact	2280
tccttcctca	gtccacctct	ctgcccacac	gccctttta	tggctctct	atttggtg	2340
gagacaaggt	ttctctcagt	agccctggct	gtccaggacc	tcactctgta	gatgaggctg	2400
gctttcaact	cacaaggctg	cctgcctggg	tgctgggatt	aaaggcgtat	gccaccacaa	2460
agaaaaaaaaaa	aa					2472

<210> 6  
 <211> 579  
 <212> PRT

<213> rattus rattus

&lt;400&gt; 6

Met Val Leu Ser Glu Val Trp Thr Thr Leu Ser Gly Val Ser Gly Val  
1 5 10 15Cys Leu Ala Cys Ser. Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr  
20 25 30Gly Arg Gln Lys Ala Arg Gly Ala Ala Thr Arg Ala Arg Gln Lys Gln  
35 40 45Arg Ala Ser Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu  
50 55 60Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Thr Leu Pro Leu Leu  
65 70 75 80Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val  
85 90 95Phe Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
100 105 110Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala  
115 120 125Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
130 135 140Phe Ser Tyr Lys Gly His Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu  
145 150 155 160Gly Met Pro Ser Glu Ser Asp Cys Val Val Val Gln Val Leu Lys Leu  
165 170 175Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu  
180 185 190Ser Phe Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp  
195 200 205Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
260 265 270

Gln Thr Ala Val Gln Leu Ser Leu Gly Pro Met Ala Arg Asp Val Glu  
275 280 285

Ser Leu Ala Leu Cys Leu Lys Ala Leu Leu Cys Glu His Leu Phe Thr  
290 295 300 305

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Arg  
305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Leu Ile Glu Thr Lys Gln Arg  
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Asn Asn Ile  
355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly  
370 375 380

Gly Arg Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
385 390 395 400

Leu Gly Asp Leu Ile Leu Ile Leu Arg Leu Pro Ser Trp Phe Lys Arg  
405 410 415

Leu Leu Ser Leu Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe  
420 425 430

Leu Asn Ser Met Arg Pro Arg Ser Ala Glu Lys Leu Trp Lys Leu Gln  
435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala  
450 455 460

Met Asn Leu Asp Val Leu Leu Thr Pro Met Leu Gly Pro Ala Leu Asp  
465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu Leu Tyr Lys Gly Tyr Phe Gly  
515 520 525

Asp Ile Trp Asp Ile Ile Leu Lys Lys Ala Met Lys Asn Ser Val Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Gln Leu Met Thr Pro Gln Lys  
 565 570 575

Gln Pro Ser

<210> 7  
 <211> 2063  
 <212> DNA  
 <213> homo sapiens

<400> 7	
tgccggccgg taggcagcag caggctgaag ggatcatggc gcagtacgag ctgtggccg	60
cgctgcctgg cgcctccggg gtcgcctgg cctgctgctt cgtggccggc gccgtggccc	120
tgcgctggtc cgggcgcggg acggcgcggg gcgcgggtgg ccgggcgcga cagaagcagc	180
gagcggccct ggagaacatg gacagggcgg cgacgcgtt ccggctccag aacccagacc	240
tggactcaga ggcgctgcta gccctgcccc tgcctcagct ggtgcagaag ttacacagta	300
gagagctggc ccctgaggcc gtgctttca cctatgtggg aaaggcctgg gaagtgaaca	360
aagggaccaa ctgtgtgacc tccatctgg ctgactgtga gactcagctg tctcaggccc	420
caaggcaggg cctgcttat ggcgtccctg tgagcctcaa ggagtgccttc acctacaagg	480
gccaggactc cacgctggc ttgagcctga atgaaggggt gccggcggag tgcgcacagcg	540
tagtggtgca tgcgtgaag ctgcagggtg ccgtgcctt cgtgcacacc aatgttccac	600
agtccatgtt cagctatgac tgcagtaacc ccctttgg ccagaccgtg aacccatgga	660
agtccctcaa aagcccaggg ggctcctcag ggggtgaagg ggccctcatac gggcttgag	720
gctcccccct gggcttaggc actgatatcg gaggcagcat ccgtttcccc tcccttct	780
gcggcatctg cggcctcaag cccacagggc accgcctcag caagagtggc ctgaaggct	840
gtgtctatgg acaggaggca gtgcgtctct ccgtggccctt catggcccg gacgtggaga	900
gcctggcaact gtgcctgcga ccctgctgt gcgaggacat gttccgcctt gaccccactg	960
tgcctccctt gcccttcaga gaagaggctt acaccagctc tcaagccctg cgtgtgggt	1020
actatgagac tgacaactat accatgcctt cccggccat gaggcggccgt gtgctggaga	1080
ccaaacacagag cttttaggtt gccccccaca cgctggttcc cttttgcata agcaacatac	1140
cccatgctct ggagaccctg tcaacagggtt ggctttcag tggatggcc cacacccctt	1200
tacagaactt caaagggtat ttgcgtggacc cctgcctggg ggacctggc tcaattctga	1260
atggcttcaa ggactgctgg ccttcctggt gaagcctctg ctgccaaggc	1320
tgtcagcttt cctcagcaac atgaagtctc gttcggtgg aaaactctgg gaactgcagc	1380
acgagatcga ggtgtaccgc aaaaccgtga ttgcccagtg gagggcgcgt gacctggatg	1440
tgggtctgac ccccatgctg gcccctgctc tggacttgaa tggccctggc agggccacag	1500
ggccgcgtcag ctacactatg ctgtacaact gcctggactt ccctgcagggtt gttggcctg	1560
tcaccacgggt gactgctgag gacgaggccc agatggaaaca ttacaggggc tactttggg	1620
atatctggga caagatgctg cagaaggcata tgaagaagag tggggcgtt ccgggtggccg	1680

tgcagtgtgt ggctctgccc tggcaagaag agttgtgtct gcgggttcatg cgggaggtgg	1740
agcgactgat gaccctgaa aagcagtcat cctgatggct ctggctccag aggacctgag	1800
actcacactc tctgcagccc agcctagtca gggcacagct gccctgctgc cacagcaagg	1860
aaatgtcccg catggggcag aggctccgt gtccctctccc ccaacccct gcaagaagcg	1920
ccgactccct gagtctggac ctccatccct gctctggcc cctctttcg tcctgatccc	1980
tccaccccca tggcagcc catggtatg acataggcca aggcccaact aacagtcaag	2040
aaacaaaaaaaaaaaaaaa aaa	2063

<210> 8  
 <211> 579  
 <212> PRT  
 <213> homo sapiens  
  
 <400> 8

Met Val Gln Tyr Glu Leu Trp Ala Ala Leu Pro Gly Ala Ser Gly Val  
 1 5 10 15

Ala Leu Ala Cys Cys Phe Val Ala Ala Val Ala Leu Arg Trp Ser  
 20 25 30

Gly Arg Arg Thr Ala Arg Gly Ala Val Val Arg Ala Arg Gln Lys Gln  
 35 40 45

Arg Ala Gly Leu Glu Asn Met Asp Arg Ala Ala Gln Arg Phe Arg Leu  
 50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Pro  
 65 70 75 80

Gln Leu Val Gln Lys Leu His Ser Arg Glu Leu Ala Pro Glu Ala Val  
 85 90 95

Leu Phe Thr Tyr Val Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn  
 100 105 110

Cys Val Thr Ser Tyr Leu Ala Asp Cys Glu Thr Gln Leu Ser Gln Ala  
 115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys  
 130 135 140

Phe Thr Tyr Lys Gly Gln Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu  
 145 150 155 160

Gly Val Pro Ala Glu Cys Asp Ser Val Val Val His Val Leu Lys Leu  
 165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe  
 180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Val Asn Pro Trp  
195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu  
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly  
225 230 235 240

Ser Ile Arg Phe Pro Ser Ser Phe Cys Gly Ile Cys Gly Leu Lys Pro  
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly  
260 265 270

Gln Glu Ala Val Arg Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu  
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg  
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Thr  
305 310 315 320

Ser Ser Gln Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr  
325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Val Leu Glu Thr Lys Gln Ser  
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Ser Asn Ile  
355 360 365

Pro His Ala Leu Glu Thr Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly  
370 375 380

Gly His Thr Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys  
385 390 395 400

Leu Gly Asp Leu Val Ser Ile Leu Lys Leu Pro Gln Trp Leu Lys Gly  
405 410 415

Leu Leu Ala Phe Leu Val Lys Pro Leu Leu Pro Arg Leu Ser Ala Phe  
420 425 430

Leu Ser Asn Met Lys Ser Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln  
435 440 445

His Glu Ile Glu Val Tyr Arg Lys Thr Val Ile Ala Gln Trp Arg Ala  
450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ala Pro Ala Leu Asp  
465 470 475 480

Leu Asn Ala Pro Gly Arg Ala Thr Gly Ala Val Ser Tyr Thr Met Leu  
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val  
500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Arg Gly Tyr Phe Gly  
515 520 525

Asp Ile Trp Asp Lys Met Leu Gln Lys Gly Met Lys Lys Ser Val Gly  
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu  
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys  
565 570 575

Gln Ser Ser

**CORRECTED VERSION**

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number  
**WO 2004/037371 A2**

(51) International Patent Classification<sup>7</sup>: B01D (US). WILSON, Sandy, J. [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). MAZUR, Curt [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).

(21) International Application Number: PCT/US2003/033354

(22) International Filing Date: 21 October 2003 (21.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/420,065 21 October 2002 (21.10.2002) US

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BARBIER, Ann, Johanna [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037

(74) Agents: ELDERKIN, Dianne et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

*[Continued on next page]*

(54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE

WO 2004/037371 A2



(57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(15) **Information about Correction:**  
see PCT Gazette No. 34/2004 of 19 August 2004, Section II

**Published:**

— *without international search report and to be republished upon receipt of that report*

(48) **Date of publication of this corrected version:**

19 August 2004

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*